PTGS2 and chronic myelogenous leukemia, BCR-ABL1 positive: CML-MSCedG-MDSC showed higher level of ARG1 (23.5±11.9, p = 0.02), IL6 (33.8±13.9, p = 0.004), IL1β (47.3±25.2, p = 0.001), COX2 (20.7±10.9, p = 0.002) and TNFα (20.8±19.3, p = 0.006) compared to HD-MSCedG-MDSC (Fig 4).